SCH 900475

humanized mouse monoclonal (228-L-proline(H10-S>P))gamma 4 heavy chain (134-218')-disulfide with humanized mouse monoclonal kappa light chain dimer (226-226'':229-229'')-bisdisulfide

MK-3475

Keytruda

immunoglobulin G4, anti-(human programmed cell death 1)

anti-PD-1 monoclonal antibody MK-3475

A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C106432" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C106432" NCI Thesaurus)

http://purl.bioontology.org/ontology/PDQ/CDR0000695789